GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Short Percentage of Float

KalVista Pharmaceuticals (STU:4XC1) Short Percentage of Float


View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of KalVista Pharmaceuticals's Short Percentage of Float

For the Biotechnology subindustry, KalVista Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KalVista Pharmaceuticals's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's Short Percentage of Float falls into.


;
;

KalVista Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Short Percentage of Float
Comparable Companies
ANAB ABUS TRVI ARVN XERS DNTH CAPR REPL CRMD GHRS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
KALV:USA 4XC1:Germany
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
Website
https://www.kalvista.com
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

KalVista Pharmaceuticals Headlines

No Headlines